FT : LSE nears $2.8bn deal for Russell Investments

The London Stock Exchange Group is nearing a deal to buy Russell Investments, the index compiler and asset manager, in a deal worth about $2.8bn that would substantially increase the UK group's American operations.

The two sides, which announced they had entered exclusive talks last month, have reached a tentative agreement on the price and structure of the deal and are planning to announce the agreement later this month, according to people familiar with the situation, reports the FT's Ed Hammond, Arash Massoudi and Neil Hume.

The talks are ongoing and exact terms over the mix of debt and equity used to fund the deal have not been decided, according to one person close to the discussions.

Another cautioned that, while advanced, the talks could still fall apart and no deal was certain.

But a deal at that size agreed would be the biggest in the LSE's 213-year history and mark its boldest push into the US where Russell is best known for its equity benchmarks such as the Russell 2000.

Owning the Russell index and its affiliated products would be a transformational leap for the LSE. It would be part of a bold push into the US market where the Russell name is prominent among traders and fund managers.

A purchase would also allow the exchange to unite the index business with FTSE International, which it owns outright after purchasing the 50 per cent it did not own from Pearson, the parent company of the Financial Times, for £450m in 2011.

Russell's business also comprises consulting and asset management, with about $260bn in assets under management.

The combination would allow the LSE to take on leaders in the indexing business – MSCI and S&P Dow Jones Indices – in a sector that has also seen Nasdaq OMX, Markit and Bloomberg further their interest and ambitions in recent years.

The LSE's move is the latest indication of how rival exchanges and financial data companies have sought to tighten their grip on market data compilers as fund managers demand more index-based products, value-added data and analytical tools.

LSE declined to comment. A spokesperson for Russell did not immediately respond to request for comment.

>>> Fed's Bullard (dove, non voter): GDP growth likely to grow in excess of 3% i

Fed's Bullard (dove, non voter): GDP growth likely to grow in excess of 3% in Q2, Q3, and Q4 - comments to reporters
- Notes that Fed could need to adjust its late Q1 2015 interest rate views in light of the lower unemployment rate 
- if unemployment drops below 6% this year, it could trigger policy adjustment discussions 
- ending reinvestment of securities can be seen as 'mild tightening', and could be useful before increasing rates

>>> Profire Energy up 20% on no news, we are looking around for a catalyst (5.0

Profire Energy up 20% on no news, we are looking around for a catalyst

PFIE is primarily a supplier of burner management systems (BMS) for the oil & gas industry. PFIE's proprietary BMS is a high-tech thermostat that monitors and manages the burner flames that are widely used in the production and transportation of oil & natural gas. Current methods to make sure burners are at the correct temp or haven't gone out are manual, inefficient, and often dangerous. PFIE's BMS electronically monitors the flames and reignites them as needed, which is a big improvement over the current manual process, and can thus can help E&P customers cut costs, improve efficiency, and reduce injuries and fatalities.

{PFIE US Equity DES <GO>}

{PFIE US Equity IGPO 5 <GO>}

>>> Achillion (ACHN) +40% : Feuerstein suggesting that ACHN may be next takeove

Achillion Pharmaceuticals TheStreet.com's Feurstein: Achillion has a pipeline of hepatitis C drugs, the most valuable, perhaps, is ACH-3422, a nucleotide NS5B polyermase inhibitor

With Merck gobbling up Idenix Pharmaceuticals, the hepatitis C takeout speculation shifts to Achillion Pharmaceuticals. Using the Idenix premium, an acquisition of Achillion would be considerably cheaper -- less than $1 billion at Friday's closing stock price. 

Like Idenix, Achillion has a pipeline of hepatitis C drugs. The most valuable, perhaps, is ACH-3422, a nucleotide NS5B polyermase inhibitor. The conventional thinking is that so-called "nucs" are the linchpin of hepatitis C combination therapy. Gilead Sciences' (GILD) Sovaldi is a nuc and will likely generate $9-10 billion in sales this year. Idenix is developing a nuc, which is probably why Merck acquired the company.